Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

r at 5:45 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

The following posters will be presented by the investigators from The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital:

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild Type c-KIT And Potential Impact On Normal Hematopoiesis.  Session Name: Molecular Pharmacology, Drug Resistance: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The Combination Of FLT3 Inhibition And Hypomethylation Confers Synergistic Antileukemic Effects On FLT3-ITD Positive AML Cell Lines And Primary Cells: Session Name: Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The abstracts and posters can be accessed on the ASH website at http://hematology.org.

Third Quarter Results
Revenues were $7.7 million and $4.3 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $3.4 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $4.5 million and $8.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The decrease of $3.7 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, in which enrollment was completed in late 2011. 

General and administrative expenses were
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015  Natera, Inc. (Nasdaq: ... and the analysis of circulating cell-free DNA, today announced ... ended June 30, 2015 after the market close on ... and webcast at 1:30 p.m. PT (4:30 p.m. ET) ... outlook.Event:Natera,s Second Quarter 2015 Results Conference Call  Date: , ...
(Date:8/3/2015)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... quarter 2015 on Monday, August 10, 2015 at 4:30 ... president and chief executive officer, will lead the call. ... results for the second quarter 2015. The ... of Halozyme,s corporate website and a recording will be ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... consumer of benzene. Benzene is processed to get such derivatives as ethylbenzene, a ... derivatives are principally used within the automotive industry for the production of tyres ...
(Date:8/3/2015)... , August 3, 2015 E-QURE ... commercialization of its Bio-electrical Signal Therapy device ("BST Device"), ... of hard to heal chronic wounds, today announced that ... Chemipal, an Israeli distributor specializing in medical devices, for ... Chemipal is a 70 years old, sales, marketing ...
Breaking Biology Technology:Natera to Release Second Quarter 2015 Results on August 12, 2015 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3
... exciting at the beginning. , ,Two companies enter into ... Web site, or have a service provider deliver a range ... work out perfectly well and the parties come to the ... has been performed or received. , ,However, sometimes the ...
...
... Fiserv Inc. has released a software suite ... , ,CRM software keeps track of the interactions between ... times, allowing the business to coordinate its customer service. ... with other systems from Fiserv, which makes a wide ...
Cached Biology Technology:Arbitration can help when IT deals go sour 2Arbitration can help when IT deals go sour 3
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... at Polytechnic Institute of New York University (NYU-Poly) have ... single virus particles in solution, an advance that may ... shrink test result wait times from weeks to minutes. ... and member of the Othmer-Jacobs Department of Chemical and ...
... is largely restricted to the eastern edge of the New England Tableland, ... raised this flowering plant, until now classified as a variety of the ... of a distinct species. The study was published in the open access ... the family of flowering plants that includes the Banksia and ...
... After waking up, the concentration of the stress hormone ... only for grown-ups but for babies as well. A ... has reported this finding in the journal Psychoneuroendocrinology ... possibility to already research the activity of the stress ...
Cached Biology News:By detecting smallest virus, researchers open possibilities for early disease detection 2By detecting smallest virus, researchers open possibilities for early disease detection 3Botany student proves 'New England Banksia' a distinct species 2New method: Research team analyzes stress biology in babies 2
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... Digital shaking water bath, with a comprehensive ... and shaking water baths with seamless, splash-water ... The bright MULTI-DISPLAY (LED) indicating up to ... the lab. Advanced MICROPROCESSOR technology with PID ...
... buffered anti-freeze environment for enzyme conjugated antibodies ... low viscosity solution at -20C , ... sampling is convenient , Contains preservatives ... Protect enzyme conjugates during storage without ...
Biology Products: